On the stock market since 1997, it operates in the world of health and science. It has 944 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
Sales run at $199.2M a year. A small number, but proof the product has real buyers.
There is $113.5M in the vault; even if every debt were paid off, $101.3M would remain.
Over the last 12 months, company executives reported 13 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $16.0M against $199.2M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, HRBR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HRBR is a high-risk stock — not yet profitable, and its future rides on its product catching on.